News

The National Institutes of Health is investing $515 million more into long COVID research efforts, three years after launching the initiative with $1.15 billion.

The cash infusion for the Recover program, announced Tuesday, will bolster ongoing research into the underlying biology and potential treatments for long COVID. NIH Director Monica Bertagnolli, M.D., said in a release that nearly 90,000 people were participating in ongoing Recover observational trials across more than 300 sites. 

By Sara Gilgore – Staff Reporter, Washington Business Journal – Feb 15, 2024 – 

It was her mother’s 86th birthday when Michelle Riley-Brown received a call that would change the trajectory of her career.

Holding the phone to her ear in her Houston home on March 3, 2023, the veteran health executive learned she was not only the first woman — but the first African American woman — to be named president and CEO of Children’s National Hospital in D.C.

The New Orleans native and youngest of five siblings — four of whom went into health care — immediately thought of her late father, a general surgeon who dedicated his life to medicine.

In January, a team of multidisciplinary doctors performed the first case in the world of using bilateral high intensity focused ultrasound (HIFU) pallidotomy on Jesus, a 22-year-old patient with dyskinetic cerebral palsy.

The procedure is part of a clinical trial led by Chima Oluigbo, M.D., pediatric neurosurgeon at Children’s National Hospital.

FREDERICK, Md., Feb. 13, 2024 /PRNewswire-PRWeb/ — Waisman Biomanufacturing, a leading contract development and manufacturing organization (CDMO) which is strategically part of the University of Wisconsin Madison, announced today a strategic partnership with RoosterBio, Inc., a leading provider of human mesenchymal stem/stromal cells (MSCs), highly engineered media solutions, and bioprocess development services.

Through this collaboration, Waisman Biomanufacturing will incorporate RoosterBio’s cutting-edge MSC and exosome bioprocessing products, manufacturing protocols, and analytical services into its portfolio of biologics manufacturing services, expanding Waisman Biomanufacturing’s capabilities for the production of advanced therapies for clinical trials.

BioHealth Innovation (BHI) is an innovation intermediary that facilitates the commercialization of emerging technologies in the BioHealth Capital Region (Maryland, DC and Virginia). We are seeking an entry-level Life Sciences Business Strategist to join our team remotely.

Biosim AI, founded by a professor at the University of Maryland in College Park, has closed on $12.25 million in its bid to commercialize technology to “enable and accelerate drug discovery at quantum accuracy.” So far, the company has raised $13 million, with investors including Armenia’s SmartGate VC, according to Crunchbase.

Armenian-born Garegin Papoian, Monroe Martin Professor at UMD’s Chemistry & Biochemistry and Institute for Physical Science and Technology, founded Biosim AI in 2020, raising a small pre-seed investment from his home country firm, SmartGate VC.

Germantown, MD, USA (February 07, 2024) – Amarex Clinical Research, LLC, an NSF company, announces December 2023 marked its 25th year advancing patient access to safe and effective clinical products through delivery of outstanding regulatory and clinical trial services to Sponsors within the life sciences industry.

Amarex was founded in 1998 by scientists from diverse backgrounds in academia, industry, and the FDA. Born from a vision of wanting better services from CRO vendors by correcting the many inefficiencies and deficiencies in the management and conduct of clinical trials, our founders revisited the clinical trial process and developed improved, cost-effective methods for clinical product development without sacrificing quality. Amarex’s unmatched value to Sponsors continues to differentiate Amarex from the competition by assigning senior level staff to every project, optimizing time and cost with efficient and effective processes and procedures, building true collaborative partnerships with Sponsors, and through a commitment to long-term client relationships in order to achieve successful clinical development program outcomes.

ROCKVILLE, Md., Feb. 7, 2024 /PRNewswire/ —  I-Mab (the “Company“) (NASDAQ: IMAB), a global biotech company exclusively focused on bringing highly differentiated immunotherapies and biologics for cancer treatment to patients around the world, today announced that as part of its strategy to become a U.S.-based biotech, its Chinese subsidiaries have entered into definitive agreements with I-Mab Biopharma (Hangzhou) Co., Ltd. (the “Hangzhou Company“), an unconsolidated affiliate of the Company, and a group of China-based investors to divest the Company’s assets and business operations in China.